Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 15:12:1303-1310.
doi: 10.2147/IDR.S199978. eCollection 2019.

The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients - a systemic review and meta-analysis of randomized controlled trials

Chih-Wei Chen  1   2 , Shen-Peng Chang  3 , Hui-Ting Huang  4 , Hung-Jen Tang  5 , Chih-Cheng Lai  6
Affiliations

The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients - a systemic review and meta-analysis of randomized controlled trials

Chih-Wei Chen et al. Infect Drug Resist. .

Abstract

Objectives: This meta-analysis aims to assess the clinical efficacy and safety of ceftaroline in treating acute bacterial infections - community-acquired pneumonia (CAP) and skin and skin structure infection (SSSI) in pediatric patients. Methods: The Pubmed, Embase, ClinicalTrials.gov. and the Cochrane databases were searched up to December 31, 2018. Only randomized controlled trials (RCTs) evaluating ceftaroline and other comparators in the treatment of acute bacterial infection in pediatric patients were included. The primary outcome was the clinical cure rate and the secondary outcome was the risk of adverse event. Results: Three RCTs were included. Overall, ceftaroline had a clinical cure rate at end of therapy (EOT) and test of cure (TOC) similar to comparators in the treatment of acute bacterial infection (at EOT, OR, 1.93; 95% CI, 0.88-4.25, I2 =0%, and at TOC, OR, 1.36; 95% CI, 0.64-2.91, I2 =14%). In addition, ceftaroline had a clinical failure rate at EOT and TOC similar to comparators in the treatment of acute bacterial infection (at EOT, OR, 0.62; 95% CI, 0.22-1.76, I2 =0%, and at TOC, OR, 0.68; 95% CI, 0.24-1.91, I2 =0%). No significant differences were found for the risk of treatment-emergent adverse events (TEAE) in all and different degrees between ceftaroline and comparators (OR, 0.81; 95% CI, 0.37-1.78, I2 =56%). The risks of TEAE and severe adverse events related to study drug were similar between ceftaroline and comparators (TEAE related to study drug, OR, 0.98; 95% CI, 0.52-1.82, I2 =0%, severe adverse event related to study drug, OR, 1.09; 95% CI, 0.22-5.44, I2 =22%). Conclusions: The clinical efficacy of ceftaroline is as good as comparator therapy in the treatment of acute bacterial infections - CAP and SSSI, and this antibiotic is well tolerated as the comparators.

Keywords: acute bacterial infection; ceftaroline; community-acquired pneumonia; pediatric; skin and skin structure infection.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
Risk of bias per study and domain. Note: +, low risk; -, high risk; ?, unknown.
Figure 3
Figure 3
The overall clinical cure rates of ceftaroline and comparators in the treatment of acute bacterial infections.
Figure 4
Figure 4
The overall clinical failure rates of ceftaroline and comparators in the treatment of acute bacterial infections.
Figure 5
Figure 5
The risk of adverse events ceftaroline and comparators in the treatment of acute bacterial infections.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lee GE, Lorch SA, Sheffler-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126:204–213. doi:10.1542/peds.2009-3109 - DOI - PMC - PubMed
    1. Lautz TB, Raval MV, Barsness KA. Increasing national burden of hospitalizations for skin and soft tissue infections in children. J Pediatr Surg. 2011;46:1935–1941. doi:10.1016/j.jpedsurg.2011.05.008 - DOI - PubMed
    1. Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr Drugs. 2003;5 Suppl 1:35–46. - PubMed
    1. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46 Suppl 5:S368–S377. doi:10.1086/533593 - DOI - PubMed
    1. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:e25–e76. doi:10.1093/cid/cir531 - DOI - PMC - PubMed